Access investment deals from longevity innovators

A holding company model for Longevity

A new class of medicine

Interested in SPVs?

Investment deals (institutional investors only)

Rejuvenation Technologies
Therapeutics Mountain View, CA, US
  • Raising
    -
  • Stage
    Series A
Mitrix Bio
Therapeutics Pleasanton, CA, US
  • Raising
    $45,000,000
  • Stage
    Series A
AKL Therapeutics
Therapeutics Stevenage, UK
  • Raising
    $15,000,000
  • Stage
    Series A
NaNotics
Therapeutics Mill Valley, CA, US
  • Raising
    $35,000,000
  • Stage
    Series B
Matter Bioworks
Therapeutics New York, NY, US
  • Raising
    $5,000,000
  • Stage
    Seed
Ridgeline Therapeutics
Therapeutics Houston, TX, US
  • Raising
    $10,000,000
  • Stage
    Series A
YouthBio Therapeutics
Therapeutics Seattle, WA, US
  • Raising
    $7,500,000
  • Stage
    Seed
NURO
Neurotech Waterloo, Canada
  • Raising
    $20,000,000
  • Stage
    Series A
Ponce De Leon Health
Supplements Fernandian Beach, FL, US
  • Raising
    $10,000,000
  • Stage
    Series C
Occuity
Medical Device Reading, UK
  • Raising
    £5,000,000
  • Stage
    Series A
Yuva Biosciences
Therapeutics Birmingham, AL, US
  • Raising
    $2,000,000
  • Stage
    Seed

Investment briefing

Full year 2022 report on the state of longevity investment: the numbers, the sectors, the top deals, the key players and the outlook for 2023:
Annual Longevity Investment Report
Read now
Investment review for January to March 2023. “If you’re going through hell, keep going.” Winston Churchill:
1st Quarter Longevity Investment Report
Read now
Disease management to disease modification – removing plaque to undo atherosclerosis:
Atherosclerosis
Read now
Delaying the menopause to increase women’s healthspan:
Reproductive longevity
Read now
Leading a new era of personalised, preventative health and optimal aging:
Longevity diagnostics
Read now
Supplementing your Longevity supplement knowledge:
Longevity supplements
Read now
Managing senescent cells to drive human longevity:
Senotherapeutics
Read now

News

Longevity investment bulletin: Modulo Bio, EVERMIND, eGenesis and more

The latest longevity updates from our investment news desk. Modulo Bio emerges…

Biophysical Therapeutics lands $100,000 investment from Reinforced Ventures

Investment will enable the longevity company to test if its patented drug…

Longevity investment bulletin: XtalPi, Levolta, MetrioPharm and more

The latest longevity updates from our investment news desk. AI drug discovery…

How to attract investors: The role of emotional storytelling in longevity investment

Why science-led companies shouldn’t lead with science. Longevity.Technology: Understanding how to attract…

Company alerts

  • June 2, 2023
    Stealth BioTherapeutics
    Stealth BioTherapeutics (NAS: MITO)
    LT 2419
    419 of 521
    Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey with mitochondrial disease and raise awareness of the unmet need our programs seek to address.
    Longevity pillar
    • Treatment
    • Prevention
    Longevity domain:
    • Longevity drugs
    • Neuropharma
    • Discovery platforms
    Longevity target: Aging Driver, Aging Disease
    and Pharmanovia partner for commercialisation of elamipretide. Read more
  • June 2, 2023
    Adiso Therapeutics
    ADISO therapeutics
    LT 2012
    12 of 521
    ADISO therapeutics creates novel therapies for inflammatory diseases. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, ADISO therapeutics are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action.
    Longevity pillar
    • Prevention
    • Treatment
    Longevity domain:
    • Longevity immunity
    Longevity target: Aging Driver
    announces the completion of a phase 1b for the treatment of moderately-to-severely active ulcerative colitis. Read more
  • June 1, 2023
    Seal Rock Therapeutics
    Seal Rock therapeutics
    LT 2394
    394 of 521
    Seal Rock therapeutics discovery and development efforts are focused on small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that when activated under a variety of stressful disease conditions can drive severe pathological outcomes including fibrosis and inflammation. The company’s lead clinical indication is non-alcoholic steatohepatitis (NASH), while its expanding R&D pipeline offers additional compelling high unmet need disease opportunities, including alcoholic hepatitis (AH), chronic kidney disease, heart failure and Parkinson’s disease
    Longevity pillar
    • Treatment
    • Prevention
    Longevity domain:
    • Longevity immunity
    • Discovery platforms
    Longevity target: Aging Disease, Aging Driver
    announces out-licensing agreement with GENFIT. Read more
  • May 31, 2023
    Humacyte
    Humacyte Inc.
    LT 2205
    205 of 521
    Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable bioengineered human tissues. The Humacyte Human Acellular Vessel (HAV) is a regenerative vascular conduit currently in various stages of clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. 
    Longevity pillar
    • Renewal
    • Treatment
    Longevity domain:
    • Regeneration
    Longevity target: Aging Disease
    grows human blood vessels and sends them to wounded Ukraine soldiers. Read more
  • May 30, 2023
    Athersys
    Athersys (NAS: ATHX)
    LT 2048
    48 of 521
    Athersys are developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell therapy platform, for disease indications in areas of neurological, inflammatory & immune, and cardiovascular disease areas, as well as other critical care indications where there is substantial unmet medical need due to the limitations in standard of care.
    Longevity pillar
    • Treatment
    • Renewal
    Longevity domain:
    • Regeneration
    Longevity target: Aging Driver, Aging Disease
    files to sell 5.685mn shares of common stock for holders. Read more
  • May 30, 2023
    Heartseed
    Heartseed
    LT 2202
    202 of 521
    Heartseed produce a large amount of ventricular type cardiomyocytes from iPS cells. Heartseeds original purification method (patented in major countries), which eliminates undifferentiated cells and non-cardiomyocytes, minimizes the risk of teratoma formation and arrhythmia.
    Longevity pillar
    • Renewal
    • Treatment
    Longevity domain:
    • Regeneration
    Longevity target: Aging Disease
    bags $14mn Series D. Read more